scholarly journals S720 Pharmacokinetics (PK), Safety, and Tolerability of Etrasimod (APD334) in Participants With Mild, Moderate, or Severe Hepatic Impairment: A Single-Dose, Open-Label, Parallel-Group Study

2021 ◽  
Vol 116 (1) ◽  
pp. S327-S328
Author(s):  
Caroline Lee ◽  
Yong Tang ◽  
Cassandra Schroeder ◽  
Jinkun Zhang ◽  
Thai Nguyen-Cleary ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Severe Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

scholarly journals Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open‐label, single‐dose, parallel‐group study

2019 ◽  
Vol 85 (9) ◽  
pp. 2011-2021 ◽  
Author(s):  
Niladri Chattopadhyay ◽  
Kai Riecke ◽  
Sandra Ligges ◽  
Torsten Zimmermann ◽  
Atef Halabi ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

Effects of hepatic impairment on the pharmacokinetics of nilotinib: An open-label, single-dose, parallel-group study

2009 ◽  
Vol 31 ◽  
pp. 2459-2469 ◽  
Author(s):  
Ophelia Q.P. Yin ◽  
Neil Gallagher ◽  
Chiaki Tanaka ◽  
Deirdre Fisher ◽  
Venkat Sethuraman ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study

2017 ◽  
Vol 57 (3) ◽  
pp. 345-354 ◽  
Author(s):  
Yves Horsmans ◽  
Jocelyn Zhou ◽  
Mateva Liudmila ◽  
George Golor ◽  
Oren Shibolet ◽  
...  
Keyword(s):  
Hepatic Impairment ◽  
Severe Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

An Open-Label, Single-Dose, Parallel-Group Study of the Effects of Chronic Hepatic Impairment on the Safety and Pharmacokinetics of Desvenlafaxine

2013 ◽  
Vol 35 (6) ◽  
pp. 782-794 ◽  
Author(s):  
Susan Baird-Bellaire ◽  
Jessica A. Behrle ◽  
Vernon D. Parker ◽  
Alain Patat ◽  
Jeffrey Paul ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study

2013 ◽  
Vol 35 (3) ◽  
pp. 215-225 ◽  
Author(s):  
Jan Peveling-Oberhag ◽  
Stefan Zeuzem ◽  
Wei Peng Yong ◽  
Tiffany Kunz ◽  
Thierry Paquet ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

scholarly journals Pharmacokinetics of serelaxin in patients with hepatic impairment: a single‐dose, open‐label, parallel group study

2015 ◽  
Vol 79 (6) ◽  
pp. 937-945 ◽  
Author(s):  
Zhanna Kobalava ◽  
Svetlana Villevalde ◽  
Yulia Kotovskaya ◽  
Holger Hinrichsen ◽  
Marc Petersen‐Sylla ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Open Label ◽  
Parallel Group Study ◽  
Parallel Group

Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning

2020 ◽  
Vol 42 (8) ◽  
pp. 1467-1482.e4 ◽  
Author(s):  
Yoshinobu Nakamaru ◽  
Masae Kakubari ◽  
Kaori Yoshida ◽  
Makoto Akimoto ◽  
Vesna Todorovic ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Severe Hepatic Impairment ◽  
Open Label
Sign in / Sign up

Export Citation Format

Share Document